Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
about
Clinical application of pharmacogenomics.Pharmacogenetics of the proton pump inhibitors: a systematic review.Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.Review article: the treatment of refractory Helicobacter pylori infection.Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.Molecular biology methods for the characterization of Helicobacter pylori infections and their diagnosis.Helicobacter pylori therapy: Present and futureRabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.CYP2C19 genotype and the PPIs--focus on rabeprazole.The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypesHelicobacter pylori eradication in West Asia: a reviewLow and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.Is There Any Difference in the Eradication Rate of Helicobacter pylori Infection According to the Endoscopic Stage of Peptic Ulcer Disease?Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese HansRandomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.Eradication of Helicobacter Pylori in Iran: A Review.
P2860
Q34280685-F57A3B95-44D9-4683-A73D-D90B647EAC2BQ34532600-C3AD4D3F-4D33-4E34-93A8-7C78B98B973FQ34706721-D68143FF-7CFB-4F79-8963-FDBF580EAB22Q35086840-7E995772-6176-44C9-ADFA-4E39875C8634Q35145092-4DA22510-A50F-4996-A9E3-C175802AC5E9Q35923954-D7C0BDED-B5CE-4871-BD32-41722ED79B70Q36028541-3F7A91F6-2757-402E-AD16-8906FCBD9A78Q36220182-1A7641B6-C0DB-4648-BF63-E49423D7F7C6Q36322095-3FC5E281-6729-447A-B082-25AA68302758Q36344158-816E3A59-D1DC-48A4-86C0-9A6300E82630Q36545135-261F3D1C-27CD-44B8-8187-C4EA043E0848Q37247036-FD09A9B2-BC37-454F-A624-770933B3B38CQ38240846-FCD3310B-FA38-4C24-9AFF-E62798CF0E0DQ39146021-31A6FD22-BD4A-4C9D-875A-A910DC0C159CQ41442357-445D8D0F-D7E4-4FDB-B2E1-1237CA94502FQ41834927-02124948-FBDC-4005-B555-C90BF13F1C27Q44066559-B478E8C2-4F0C-4335-B6EE-69C0D98F8A9EQ44471231-3FAD349C-BFFF-4623-B54E-A96C4C67919EQ44487374-1667C01F-AB92-45A2-8709-63F830D67C9AQ44668880-E75EA9EB-9F80-41B6-9404-7D60F7C4A76BQ45269497-9FF97698-44EF-4A67-BD0F-8243C9E629E1Q52571225-3C90CE1B-8B8E-40F0-8E20-65B2EE14E92C
P2860
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@en
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@nl
type
label
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@en
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@nl
prefLabel
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@en
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@nl
P2093
P2860
P1476
Efficacy of triple therapy wit ...... CYP2C19 genetic polymorphism.
@en
P2093
J Ishizuka
K Nishikawa
P2860
P304
P356
10.1046/J.1365-2036.2001.01063.X
P407
P577
2001-09-01T00:00:00Z